Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination With Paclitaxel vs. Paclitaxel Alone in Patients With Metastatic or Locally Recurrent Breast Cancer
Sponsor: Millennium Pharmaceuticals, Inc.
A PHASE2 clinical study on Breast Cancer and Breast Carcinoma, this trial is completed. The trial is conducted by Millennium Pharmaceuticals, Inc. and has accumulated 16 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Nov 2024 — Sep 2025 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 11 earlier versions
-
Dec 2022 — Sep 2023 [monthly]
Active Not Recruiting PHASE2
-
Jun 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE2
-
Jan 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Nov 2019 — Sep 2020 [monthly]
Active Not Recruiting PHASE2
-
Jan 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE2
-
Jul 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Feb 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Millennium Pharmaceuticals, Inc.
- US Oncology Research
For direct contact, visit the study record on ClinicalTrials.gov .